Statistical characteristics of finger-tapping data in Huntington's disease.

Antoniades CA, Ober J, Hicks S, Siuda G, Carpenter RH, Kennard C, Nemeth AH.

Med Biol Eng Comput. 2012 Apr;50(4):341-6. doi: 10.1007/s11517-012-0863-2.

How can human pluripotent stem cells help decipher and cure Huntington's disease?

Perrier A, Peschanski M.

Cell Stem Cell. 2012 Aug 3;11(2):153-61. doi: 10.1016/j.stem.2012.07.015.

Deficits in selective attention in symptomatic Huntington disease: assessment using an attentional blink paradigm.

Georgiou-Karistianis N, Farrow M, Wilson-Ching M, Churchyard A, Bradshaw JL, Sheppard DM.

Cogn Behav Neurol. 2012 Mar;25(1):1-6. doi: 10.1097/WNN.0b013e318248c503.

Reversible acute chorea in a patient with diabetes treated with hemodialysis.

Rozenberg E, Telman G.

J Clin Neurosci. 2012 Aug;19(8):1179. doi: 10.1016/j.jocn.2012.01.021.

Substance abuse may be a risk factor for earlier onset of Huntington disease.

Byars JA, Beglinger LJ, Moser DJ, Gonzalez-Alegre P, Nopoulos P.

J Neurol. 2012 Sep;259(9):1824-31. doi: 10.1007/s00415-012-6415-8.

Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.

Dong X, Zong S, Witting A, Lindenberg KS, Kochanek S, Huang B.

J Gene Med. 2012 Jul;14(7):468-81. doi: 10.1002/jgm.2641.

Ectopic theta oscillations and interictal activity during slow-wave state in the R6/1 mouse model of Huntington's disease."

Pignatelli M, Lebreton F, Cho YH, Leinekugel X.

Neurobiol Dis. 2012 Dec;48(3):409-17. doi: 10.1016/j.nbd.2012.07.015.

Androgen function in the pathophysiology and treatment of male Huntington's disease patients.

Ransome MI.

J Neuroendocrinol. 2012 Oct;24(10):1275-83. doi: 10.1111/j.1365-2826.2012.02347.x. Review.

Genetic analysis of polymorphisms in the kalirin gene for association with age-at-onset in European Huntington disease patients.

Tsai YC, Metzger S, Riess O, Soehn AS, Nguyen HP.

BMC Med Genet. 2012 Jun 21;13:48. doi: 10.1186/1471-2350-13-48.

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW.

Neuron. 2012 Jun 21;74(6):1031-44. doi: 10.1016/j.neuron.2012.05.009.

Optineurin in Huntington's disease intranuclear inclusions.

Schwab C, Yu S, McGeer EG, McGeer PL.

Neurosci Lett. 2012 Jan 6;506(1):149-54. doi: 10.1016/j.neulet.2011.10.070.

A greatly extended PPARGC1A genomic locus encodes several new brain-specific isoforms and influences Huntington disease age of onset.

Soyal SM, Felder TK, Auer S, Hahne P, Oberkofler H, Witting A, Paulmichl M, Landwehrmeyer GB, Weydt P, Patsch W; European Huntington Disease Network..

Hum Mol Genet. 2012 Aug 1;21(15):3461-73. doi: 10.1093/hmg/dds177.

Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.

Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating N, Ruiz M, Mushlin R, Alosio W, McConnell K, Connor D, Murphy C, Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, Park LC

PLoS One. 2012;7(12):e49838. doi: 10.1371/journal.pone.0049838.

Treatment of depressive-like behaviour in Huntington's disease mice by chronic sertraline and exercise.

Renoir T, Pang TY, Zajac MS, Chan G, Du X, Leang L, Chevarin C, Lanfumey L, Hannan AJ.

Br J Pharmacol. 2012 Mar;165(5):1375-89. doi: 10.1111/j.1476-5381.2011.01567.x.

Huntington disease and the huntingtin protein.

Zheng Z, Diamond MI.

Prog Mol Biol Transl Sci. 2012;107:189-214. doi: 10.1016/B978-0-12-385883-2.00010-2. Review.